The deal size was increased to $175M from $150M and priced at low end of $16.00-$16.15 range. JPMorgan, Morgan Stanley, Leerink and TD Cowen are acting as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RCKT:
- Rocket (NASDAQ: RCKT) Rockets Ahead with FDA Alignment on Danon Disease Trial
- Rocket Pharmaceuticals jumps 31% after announcing FDA alignment on Ph.2 RP-A401
- Rocket Pharmaceuticals announces $150M common stock offering
- Rocket Pharmaceuticals reaches FDA alignment on Phase 2 RP-A401 trial design
- Rocket Pharmaceuticals price target lowered to $47 from $49 at Canaccord
